Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Recombinant Fusion Proteins"" wg kryterium: Temat


Tytuł:
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.
Autorzy:
Lim SY; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Lee J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Osuna CE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Vikhe P; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Schalk DR; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Chen E; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Fray E; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Kumar M; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Schultz-Darken N; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Rakasz E; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Capuano S; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Ladd RA; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Gil HM; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Evans DT; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Jeng EK; Altor Biosciences, Miramar, FL 33027, USA.
Seaman M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Martin M; Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Van Dorp C; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Perelson AS; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.; Santa Fe Institute, Santa Fe, NM 87501, USA.
Wong HC; Altor Biosciences, Miramar, FL 33027, USA.
Siliciano JD; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Siliciano R; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Safrit JT; ImmunityBio, Culver City, CA 90232, USA.
Nixon DF; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Soon-Shiong P; ImmunityBio, Culver City, CA 90232, USA.
Nussenzweig M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.; Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.
Whitney JB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.; Department of Biology, Boston College, Chestnut Hill, MA 02467, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Mar 08; Vol. 383 (6687), pp. 1104-1111. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-Retroviral Agents*/therapeutic use
Anti-Retroviral Agents*/pharmacology
Simian Acquired Immunodeficiency Syndrome*/drug therapy
Simian Acquired Immunodeficiency Syndrome*/therapy
Simian Immunodeficiency Virus*
Recombinant Fusion Proteins*/administration & dosage
Recombinant Fusion Proteins*/pharmacology
Animals ; Humans ; Broadly Neutralizing Antibodies/administration & dosage ; CD8-Positive T-Lymphocytes/virology ; Immunotherapy ; Macaca mulatta ; Viral Load ; Remission Induction ; Drug Therapy, Combination
Czasopismo naukowe
Tytuł:
Engineering Bacteriophytochrome-coupled Photoactivated Adenylyl Cyclases for Enhanced Optogenetic cAMP Modulation.
Autorzy:
Xu Q; Department of Biochemistry, University of Bayreuth, 95447 Bayreuth, Germany.
Vogt A; Charité - University Medicine Berlin, Department of Neurology with Experimental Neurology, 10117 Berlin, Germany. Electronic address: https://twitter.com/ArendVogt.
Frechen F; Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany.
Yi C; Department of Biochemistry, University of Bayreuth, 95447 Bayreuth, Germany.
Küçükerden M; Department of Biomedical Sciences, Institute of Neurosciences, University of Barcelona, 08036 Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.
Ngum N; College of Health and Life Sciences, Aston University, Birmingham B4 7ET, United Kingdom.
Sitjà-Roqueta L; Department of Biomedical Sciences, Institute of Neurosciences, University of Barcelona, 08036 Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.
Greiner A; Macromolecular Chemistry and Bavarian Polymer Institute, University of Bayreuth, Bayreuth 95440, Germany.
Parri R; College of Health and Life Sciences, Aston University, Birmingham B4 7ET, United Kingdom.
Masana M; Department of Biomedical Sciences, Institute of Neurosciences, University of Barcelona, 08036 Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain. Electronic address: https://twitter.com/mercemasana.
Wenger N; Charité - University Medicine Berlin, Department of Neurology with Experimental Neurology, 10117 Berlin, Germany.
Wachten D; Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany. Electronic address: https://twitter.com/DagmarWachten.
Möglich A; Department of Biochemistry, University of Bayreuth, 95447 Bayreuth, Germany; Bayreuth Center for Biochemistry & Molecular Biology, Universität Bayreuth, 95447 Bayreuth, Germany; North-Bavarian NMR Center, Universität Bayreuth, 95447 Bayreuth, Germany. Electronic address: .
Pokaż więcej
Źródło:
Journal of molecular biology [J Mol Biol] 2024 Mar 01; Vol. 436 (5), pp. 168257. Date of Electronic Publication: 2023 Aug 31.
Typ publikacji:
Journal Article
MeSH Terms:
Adenylyl Cyclases*/chemistry
Adenylyl Cyclases*/genetics
Cyclic AMP*/chemistry
Phytochrome*/chemistry
Phytochrome*/genetics
Recombinant Fusion Proteins*/chemistry
Recombinant Fusion Proteins*/genetics
Deinococcus*
Photoreceptors, Microbial*/chemistry
Photoreceptors, Microbial*/genetics
Animals ; Light ; Optogenetics ; Signal Transduction ; Protein Engineering
Czasopismo naukowe
Tytuł:
rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
Autorzy:
Lee M; Research Institute of NeoImmuneTech, Co., Ltd, Pohang, Korea (the Republic of).
Im SK; Research Institute of NeoImmuneTech, Co., Ltd, Pohang, Korea (the Republic of).
Baek S; Research Institute of NeoImmuneTech, Co., Ltd, Pohang, Korea (the Republic of).
Ji M; Research Institute of NeoImmuneTech, Co., Ltd, Pohang, Korea (the Republic of).
Kim M; Research Institute of NeoImmuneTech, Co., Ltd, Pohang, Korea (the Republic of).
Lee EJ; Research Institute of NeoImmuneTech, Co., Ltd, Pohang, Korea (the Republic of).
Ji ST; Research Institute of NeoImmuneTech, Co., Ltd, Pohang, Korea (the Republic of).
Ferrando-Martinez S; NeoImmuneTech, Inc, Rockville, Maryland, USA.
Wolfarth A; NeoImmuneTech, Inc, Rockville, Maryland, USA.
Lee JY; Selecxine, Pohang, Korea (the Republic of).
Kim D; Selecxine, Pohang, Korea (the Republic of).
Choi D; Research Institute of NeoImmuneTech, Co., Ltd, Pohang, Korea (the Republic of) .
Pokaż więcej
Źródło:
Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Mar 12; Vol. 12 (3). Date of Electronic Publication: 2024 Mar 12.
Typ publikacji:
Journal Article
MeSH Terms:
CD8-Positive T-Lymphocytes*
Neoplasms*
Recombinant Fusion Proteins*
Interleukin-7*
Humans ; Animals ; Mice ; Tumor Microenvironment ; Programmed Cell Death 1 Receptor ; Immunologic Factors
Czasopismo naukowe
Tytuł:
Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry.
Autorzy:
Kishnani PS; Department of Pediatrics, Duke University Medical Center, 2351 Erwin Road, Durham, NC, 27710, USA. .
Martos-Moreno GÁ; Hospital Infantil Universitario Niño Jesús, IIS La Princesa, Universidad Autónoma de Madrid, CIBERobn, ISCIII, Madrid, Spain.
Linglart A; Paris-Saclay University, AP-HP and INSERM, Paris, France.
Petryk A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Messali A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Fang S; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Rockman-Greenberg C; University of Manitoba, Winnipeg, MB, Canada.
Ozono K; Osaka University, Suita, Osaka, Japan.
Högler W; Johannes Kepler University Linz, Linz, Austria.
Seefried L; University of Würzburg, Würzburg, Germany.
Dahir KM; Vanderbilt University Medical Center, Nashville, TN, USA.
Pokaż więcej
Źródło:
Orphanet journal of rare diseases [Orphanet J Rare Dis] 2024 Mar 08; Vol. 19 (1), pp. 109. Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Journal Article
MeSH Terms:
Hypophosphatasia*/drug therapy
Chronic Pain*
Immunoglobulin G*
Recombinant Fusion Proteins*
Adult ; Humans ; Alkaline Phosphatase/therapeutic use ; Quality of Life ; Prospective Studies ; Registries ; Enzyme Replacement Therapy/methods
Czasopismo naukowe
Tytuł:
Autorzy:
Hassel JC
Berking C
Pokaż więcej
Transliterated Title:
3-Jahres-Update zur Therapie mit Tebentafusp beim metastasierten Uveamelanom.
Źródło:
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG [J Dtsch Dermatol Ges] 2024 Mar; Vol. 22 (3), pp. 485-487.
Typ publikacji:
Journal Article
MeSH Terms:
Melanoma*
Uveal Neoplasms*
Neoplasms, Second Primary*
Recombinant Fusion Proteins*
Humans
SCR Disease Name:
Uveal melanoma
Czasopismo naukowe
Tytuł:
Dulaglutide treatment reverses depression-like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress.
Autorzy:
Jin M; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Zhang S; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Huang B; Neuroscience Research Center, Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang, China.
Li L; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Liang H; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.; Cardiology Department, Hebei General Hospital, Shijiazhuang, China.
Ni A; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Han L; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Liang P; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Liu J; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Shi H; Nursing School, Hebei Medical University, Shijiazhuang, China.
Lv P; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Pokaż więcej
Źródło:
Brain and behavior [Brain Behav] 2024 Mar; Vol. 14 (3), pp. e3448.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Depression*/drug therapy
Antidepressive Agents*/pharmacology
Antidepressive Agents*/therapeutic use
Immunoglobulin Fc Fragments*
Recombinant Fusion Proteins*
Glucagon-Like Peptides/*analogs & derivatives
Animals ; Mice ; Homeostasis ; Biomarkers
Czasopismo naukowe
Tytuł:
Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment.
Autorzy:
Symington E; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Rangarajan S; Faculty of Medicine, University of Southampton, Southampton, UK.
Lester W; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Madan B; Guy's and St Thomas' NHS Foundation Trust, London, UK.
Pierce GF; Independent Consultant, La Jolla, California, USA.
Raheja P; Haemophilia Centre Royal London Hospital, Barts Health NHS Trust, London, UK.
Robinson TM; BioMarin Pharmaceutical Inc., Novato, California, USA.
Osmond D; BioMarin Pharmaceutical Inc., Novato, California, USA.
Russell CB; BioMarin Pharmaceutical Inc., Novato, California, USA.
Vettermann C; BioMarin Pharmaceutical Inc., Novato, California, USA.
Agarwal SK; BioMarin Pharmaceutical Inc., Novato, California, USA.
Li M; BioMarin Pharmaceutical Inc., Novato, California, USA.
Wong WY; BioMarin Pharmaceutical Inc., Novato, California, USA.
Laffan M; Centre for Haematology, Imperial College London, London, UK.
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2024 Mar; Vol. 30 (2), pp. 320-330. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article
MeSH Terms:
Hemophilia A*/complications
Hemostatics*
Neoplasms*/complications
Dependovirus*
Recombinant Fusion Proteins*
Adult ; Humans ; Male ; Factor VIII/genetics ; Hemorrhage/prevention & control
SCR Organism:
Adeno-associated virus-5
Czasopismo naukowe
Tytuł:
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing.
Autorzy:
Kodjikian L; Department of Ophthalmology, Croix-Rousse Teaching Hospital, Hospices Civils de Lyon, Lyon, France. .; UMR-CNRS 5510 Matéis, Villeurbanne, Université Claude Bernard Lyon 1, University of Lyon, Lyon, France. .
Arias Barquet L; Department of Ophthalmology, Hospital Universitario de Bellvitge, Barcelona, Spain.; Department of Ophthalmology, University of Barcelona, Barcelona, Spain.
Papp A; Department of Ophthalmology, Semmelweis University, Budapest, Hungary.
Kertes PJ; The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada.
Midena E; Department of Ophthalmology, University Hospital, Padua, Italy.
Ernest J; Axon Clinical Research Center, Prague, Czech Republic.
Silva R; Coimbra Institute for Clinical and Biomedical Research Faculty of Medicine (iCBR-FMUC), University of Coimbra, Coimbra, Portugal.; Ophthalmology Department, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal.; Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal.; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal.
Schmelter T; Bayer AG, Berlin, Germany.
Niesen T; Bayer AG, Berlin, Germany.
Leal S; Bayer Consumer Care AG, Basel, Switzerland.
Pokaż więcej
Źródło:
Advances in therapy [Adv Ther] 2024 Mar; Vol. 41 (3), pp. 1010-1024. Date of Electronic Publication: 2024 Jan 06.
Typ publikacji:
Clinical Trial, Phase III; Equivalence Trial; Journal Article; Randomized Controlled Trial
MeSH Terms:
Macular Degeneration*/drug therapy
Receptors, Vascular Endothelial Growth Factor*/therapeutic use
Recombinant Fusion Proteins*/therapeutic use
Humans ; Middle Aged ; Intravitreal Injections ; Treatment Outcome ; Visual Acuity ; Aged
Czasopismo naukowe
Tytuł:
Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil.
Autorzy:
Fernandes BD; Unidade de Avaliação de Tecnologias em Saúde, Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brasil.
D'Athayde Rodrigues F; Universidade Federal do Rio Grande do Sul, Porto Alegre - RS, Brasil. Electronic address: .
Cardoso Cirilo HN; Núcleo de Avaliação de Tecnologias em Saúde, Hospital das Clínicas da Universidade Federal de Goiás/Ebserh, Goiânia - GO.
Borges SS; Unidade de Avaliação de Tecnologias em Saúde, Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brasil.
Krug BC; Secretaria Estadual da Saúde do Rio Grande do Sul, Porto Alegre, RS - Brasil.
Probst LF; Unidade de Avaliação de Tecnologias em Saúde, Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brasil.
Zimmermann I; Universidade de Brasília, Brasília - DF, Brasil.
Pokaż więcej
Źródło:
Value in health regional issues [Value Health Reg Issues] 2024 Mar; Vol. 40, pp. 108-117. Date of Electronic Publication: 2024 Jan 05.
Typ publikacji:
Journal Article
MeSH Terms:
Muscular Atrophy, Spinal*/drug therapy
Oligonucleotides*
Biological Products*
Recombinant Fusion Proteins*
Pyrimidines*
Azo Compounds*
Humans ; Brazil ; Cost-Benefit Analysis
Czasopismo naukowe
Tytuł:
Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial.
Autorzy:
Li S; Department of Ophthalmology, Qilu Hospital of Shandong Province, Jinan, China.
Tao Y; Department of Ophthalmology, The Second People's Hospital of Jinan, Jinan, China.
Yang M; Department of Ophthalmology, Qilu Hospital of Shandong Province, Jinan, China.
Zhao H; Department of Ophthalmology, Qilu Hospital of Shandong Province, Jinan, China.
Si M; Department of Ophthalmology, Qilu Hospital of Shandong Province, Jinan, China.
Cui W; Department of Ophthalmology, Qilu Hospital of Shandong Province, Jinan, China.
Wang H; Department of Ophthalmology, Qilu Hospital of Shandong Province, Jinan, China.
Pokaż więcej
Źródło:
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Feb 22; Vol. 15, pp. 1286736. Date of Electronic Publication: 2024 Feb 22 (Print Publication: 2024).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Diabetic Retinopathy*/drug therapy
Diabetic Retinopathy*/surgery
Macular Edema*/drug therapy
Macular Edema*/surgery
Diabetes Mellitus*/drug therapy
Recombinant Fusion Proteins*
Receptors, Vascular Endothelial Growth Factor*
Humans ; Angiogenesis Inhibitors/therapeutic use ; Vascular Endothelial Growth Factor A ; Retina ; Laser Coagulation ; Neovascularization, Pathologic/drug therapy ; Lasers
Czasopismo naukowe
Tytuł:
Efficacy and safety of intravitreal injections of conbercept for the treatment of idiopathic choroidal neovascularization.
Autorzy:
Zhai G; Zibo Central Hospital, Zibo, China.
Su Y; Zibo Central Hospital, Zibo, China.
Wang S; Zibo Central Hospital, Zibo, China.
Lu H; Zibo Central Hospital, Zibo, China.
Liu N; Zibo Central Hospital, Zibo, China. .
Pokaż więcej
Źródło:
BMC ophthalmology [BMC Ophthalmol] 2024 Feb 19; Vol. 24 (1), pp. 75. Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:
Journal Article
MeSH Terms:
Choroidal Neovascularization*/diagnosis
Retinal Detachment*/drug therapy
Recombinant Fusion Proteins*
Humans ; Intravitreal Injections ; Vascular Endothelial Growth Factor A ; Retrospective Studies ; Retina ; Tomography, Optical Coherence ; Angiogenesis Inhibitors/therapeutic use ; Treatment Outcome ; Fluorescein Angiography
Czasopismo naukowe
Tytuł:
Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?
Autorzy:
Ozsaygılı C; Department of Ophthalmology, University of Health Sciences, Kayseri City Training and Research Hospital, Kocasinan, Kayseri, Turkey. .
Bayram N; University of Health Sciences, Ankara Etlik City Hospital, Yenimahalle, Ankara, Turkey.
Pokaż więcej
Źródło:
International ophthalmology [Int Ophthalmol] 2024 Feb 09; Vol. 44 (1), pp. 51. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Journal Article
MeSH Terms:
Macular Edema*/diagnosis
Macular Edema*/drug therapy
Macular Edema*/etiology
Diabetic Retinopathy*/complications
Diabetic Retinopathy*/diagnosis
Diabetic Retinopathy*/drug therapy
Macula Lutea*
Diabetes Mellitus*
Recombinant Fusion Proteins*
Receptors, Vascular Endothelial Growth Factor*
Humans ; Tomography, Optical Coherence ; Dexamethasone ; Biomarkers ; Intravitreal Injections ; Angiogenesis Inhibitors/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
Autorzy:
Burge DJ; Resolve Therapeutics, Miami, Florida, USA.
Werth VP; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Boackle SA; University of Colorado School of Medicine, Aurora, Colorado, USA.
Posada J; Resolve Therapeutics, Miami, Florida, USA .
Pokaż więcej
Źródło:
Lupus science & medicine [Lupus Sci Med] 2024 Feb 07; Vol. 11 (1). Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
MeSH Terms:
Lupus Erythematosus, Systemic*
Lupus Erythematosus, Discoid*/chemically induced
Lupus Erythematosus, Discoid*/drug therapy
Recombinant Fusion Proteins*
Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Treatment Outcome ; Ribonucleases/therapeutic use ; Immunoglobulin G/therapeutic use ; RNA/therapeutic use
Czasopismo naukowe
Tytuł:
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
Autorzy:
Garbowski MW; UCL Cancer Institute Hematology Department, University College London, University College London Hospitals, London, UK.
Ugidos M; BMS Center for Innovation and Translational Research Europe (CITRE), Bristol Myers Squibb, Seville, Spain.
Risueño A; BMS Center for Innovation and Translational Research Europe (CITRE), Bristol Myers Squibb, Seville, Spain.
Shetty JK; Celgene International Sàrl a Bristol-Myers Squibb Company, Boudry, Switzerland.
Schwickart M; Formerly Bristol Myers Squibb, Summit, New Jersey, USA.
Hermine O; Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.; Imagine Institute, INSERM Unité 1163, University of Paris, Paris, France.
Porter JB; UCL Cancer Institute Hematology Department, University College London, University College London Hospitals, London, UK.
Thakurta A; Formerly Bristol Myers Squibb, Summit, New Jersey, USA.
Vodala S; Britstol Myers Squibb, Princeton, NJ, USA.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2024 Feb; Vol. 99 (2), pp. 182-192. Date of Electronic Publication: 2023 Oct 02.
Typ publikacji:
Journal Article
MeSH Terms:
Iron*
Thalassemia*/complications
Immunoglobulin Fc Fragments*
Recombinant Fusion Proteins*
Activin Receptors, Type II*
Adult ; Humans ; Hepcidins ; Erythropoiesis/physiology ; Receptors, Transferrin ; Ferritins
Czasopismo naukowe
Tytuł:
Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
Autorzy:
Huang L; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Qian G; Department of Cardiovascular Medicine, Center for Circadian Metabolism and Cardiovascular Disease, The First Affiliated Hospital of Army Medical University, Chongqing, China.
Zhang H; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Li Q; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Chen L; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Tang X; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Zhao H; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Pokaż więcej
Źródło:
Lupus [Lupus] 2024 Feb; Vol. 33 (2), pp. 172-175. Date of Electronic Publication: 2023 Dec 11.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Lupus Erythematosus, Systemic*/drug therapy
Lupus Nephritis*/drug therapy
Recombinant Fusion Proteins*
Humans ; Female ; Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; Treatment Outcome ; Immunosuppressive Agents/therapeutic use
Czasopismo naukowe
Tytuł:
A potential bilayer skin substitute based on electrospun silk-elastin-like protein nanofiber membrane covered with bacterial cellulose.
Autorzy:
Feng Z; Key Laboratory of Engineering Biology for Low-Carbon Manufacturing, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, 32 West 7th Avenue, Tianjin Airport Economic Area, Tianjin 300308, China.
Wang S; Key Laboratory of Engineering Biology for Low-Carbon Manufacturing, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, 32 West 7th Avenue, Tianjin Airport Economic Area, Tianjin 300308, China.
Huang W; College of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China.
Bai W; Key Laboratory of Engineering Biology for Low-Carbon Manufacturing, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, 32 West 7th Avenue, Tianjin Airport Economic Area, Tianjin 300308, China. Electronic address: .
Pokaż więcej
Źródło:
Colloids and surfaces. B, Biointerfaces [Colloids Surf B Biointerfaces] 2024 Feb; Vol. 234, pp. 113677. Date of Electronic Publication: 2023 Nov 29.
Typ publikacji:
Journal Article
MeSH Terms:
Skin, Artificial*
Nanofibers*/chemistry
Recombinant Fusion Proteins*
Cellulose/pharmacology ; Silk/chemistry ; Elastin/chemistry
Czasopismo naukowe
Tytuł:
Identification and Analysis of DNA Methylation Inflammation-Related Key Genes in Intracerebral Hemorrhage.
Autorzy:
Xu S; Changchun University of Traditional Chinese Medicine, Changchun, China.
Wu Q; Xin Yang Central Hospital, Xinyang, China.
Tang Z; Changchun University of Traditional Chinese Medicine, Changchun, China.
Li P; Changchun University of Traditional Chinese Medicine, Changchun, China. .
Pokaż więcej
Źródło:
Biochemical genetics [Biochem Genet] 2024 Feb; Vol. 62 (1), pp. 395-412. Date of Electronic Publication: 2023 Jun 24.
Typ publikacji:
Journal Article
MeSH Terms:
DNA Methylation*
Gene Expression Profiling*
Elastin*
Recombinant Fusion Proteins*
Silk*
Humans ; Phosphatidylinositol 3-Kinases/genetics ; Gene Expression Regulation, Neoplastic ; Biomarkers ; Cerebral Hemorrhage/genetics ; Inflammation/genetics
Czasopismo naukowe
Tytuł:
The impact of COVID-19 on aflibercept treatment of neovascular AMD in Sweden - data from the Swedish Macula Register.
Autorzy:
Wickman I; Department of Ophthalmology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. .
Lövestam-Adrian M; Department of Ophthalmology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.; Department of Ophthalmology, Skåne University Hospital, Lund, Sweden.
Granstam E; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.; Department of Ophthalmology, Uppsala University Hospital, Uppsala, 751 85, Sweden.
Kjellström U; Department of Ophthalmology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.; Department of Ophthalmology, Skåne University Hospital, Lund, Sweden.
Schroeder M; Department of Ophthalmology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.; Department of Ophthalmology, Skåne University Hospital, Lund, Sweden.
Pokaż więcej
Źródło:
BMC ophthalmology [BMC Ophthalmol] 2024 Jan 30; Vol. 24 (1), pp. 49. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
COVID-19*/epidemiology
Wet Macular Degeneration*/drug therapy
Wet Macular Degeneration*/epidemiology
Recombinant Fusion Proteins*
Receptors, Vascular Endothelial Growth Factor*
Humans ; Angiogenesis Inhibitors/therapeutic use ; Ranibizumab ; Sweden/epidemiology ; Pandemics ; Vascular Endothelial Growth Factor A ; Intravitreal Injections ; Visual Acuity ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Differences in aqueous humor protein profiles in patients with proliferative diabetic retinopathy before and after aflibercept treatment.
Autorzy:
Wang T; Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No 1 Shuai Fu Yuan, Dongcheng District, Beijing, 100730, China.; Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Chen H; Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No 1 Shuai Fu Yuan, Dongcheng District, Beijing, 100730, China.; Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Du X; Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No 1 Shuai Fu Yuan, Dongcheng District, Beijing, 100730, China.; Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Bintao Qiu MM; Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Li N; Operating Room, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Min H; Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No 1 Shuai Fu Yuan, Dongcheng District, Beijing, 100730, China. .; Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China. .; Department of Ophthalmology, Aier Eye Hospital, Tianjin University, Nankai District, Kanfu Road No. 102, Tianjin, China. .
Pokaż więcej
Źródło:
BMC ophthalmology [BMC Ophthalmol] 2024 Jan 22; Vol. 24 (1), pp. 32. Date of Electronic Publication: 2024 Jan 22.
Typ publikacji:
Journal Article
MeSH Terms:
Diabetic Retinopathy*/drug therapy
Diabetes Mellitus*
Recombinant Fusion Proteins*
Humans ; Aqueous Humor ; Vascular Endothelial Growth Factor A ; Receptors, Vascular Endothelial Growth Factor/therapeutic use
Czasopismo naukowe
Tytuł:
Effect of polyp regression and reduction on treatment efficacy in polypoidal choroidal vasculopathy treated with aflibercept.
Autorzy:
Sayanagi K; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan. .
Fujimoto S; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Hara C; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Fukushima Y; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Maruyama K; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Kawasaki R; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Sato S; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Nishida K; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Jan 21; Vol. 14 (1), pp. 1833. Date of Electronic Publication: 2024 Jan 21.
Typ publikacji:
Journal Article
MeSH Terms:
Macula Lutea*
Polyps*/drug therapy
Recombinant Fusion Proteins*
Receptors, Vascular Endothelial Growth Factor*
Humans ; Polypoidal Choroidal Vasculopathy ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies